<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101759</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/20/0490</org_study_id>
    <nct_id>NCT05101759</nct_id>
  </id_info>
  <brief_title>Impact of Chemotherapeutic Treatments in Patients Aged 7 Treated for Lymphoid Hematological Malignancy</brief_title>
  <acronym>LYMPHOLD</acronym>
  <official_title>Impact of Chemotherapeutic Treatments on Functional Autonomy and Quality of Life in Patients Aged 75 Years and Over Treated for Lymphoid Hematological Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the prevalence of functional decline in elderly patients&#xD;
      treated with chemotherapy or immunochemotherapy for lymphoid hematologic malignancies. For&#xD;
      this purpose, each patient benefits at inclusion (D0) of a standardized gerontological&#xD;
      evaluation, and 3 and 6 months post-inclusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to contribute to the improvement of the hematological management of&#xD;
      elderly patients. Indeed, the majority of hematological malignancies are diagnosed in&#xD;
      subjects aged 65 years and over. Hematologists are therefore increasingly confronted with the&#xD;
      complexity of managing elderly patients. The high prevalence of comorbidities and/or&#xD;
      geriatric syndromes (cognitive disorders, malnutrition, loss of functional autonomy, etc.)&#xD;
      contributes to the great heterogeneity of this population and to the complexity of&#xD;
      therapeutic decisions.&#xD;
&#xD;
      The comprehensive geriatric assessment (CGA), recommended by the International Society of of&#xD;
      Onco-Geriatrics (SIOG), allows to better understand this heterogeneity and to define an&#xD;
      individualized management. Numerous studies have demonstrated the value of the CGA in&#xD;
      predicting the risk of treatment toxicity and morbidity in geriatric hematology. However,&#xD;
      beyond life expectancy, the maintenance of quality of life and/or functional autonomy&#xD;
      represent major parameters to be integrated into the therapeutic decision. These two&#xD;
      parameters are not sufficiently taken into account in hematology clinical trials. In the vast&#xD;
      majority of these studies, the criteria of interest remain purely hematological (overall&#xD;
      survival, toxicity, relapse-free survival, etc.). This approach may even be responsible for&#xD;
      an increased risk of toxicity when the chemotherapy protocols proposed to elderly patients&#xD;
      are based on the same objectives as those for younger subjects. It therefore seems essential&#xD;
      to change the paradigm by integrating major geriatric criteria into the methodology of&#xD;
      clinical trials of hematological malignancies in elderly patients.&#xD;
&#xD;
      The main objective of our study is therefore to evaluate the prevalence of functional decline&#xD;
      in a population of elderly patients treated with chemotherapy or immuno-chemotherapy for&#xD;
      lymphoid hemopathies. For this purpose, each patient benefits at inclusion (D0) of a&#xD;
      standardized gerontological evaluation, and 3 and 6 months post-inclusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functionnal Decline</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of patients with functional decline at 6 months. Functional decline was defined as a loss of 0.5 points or more on the ADL at 6 months compared with inclusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional performance</measure>
    <time_frame>6 months</time_frame>
    <description>A loss of at least 1 point in the SPPB score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity assessed according to NCI-CTCAE v5</measure>
    <time_frame>6 months</time_frame>
    <description>Events of Toxicity will be assessed according to NCI-CTCAE v5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Institutionalization</measure>
    <time_frame>6 months</time_frame>
    <description>Ratio of institutionalized patients to total patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early death</measure>
    <time_frame>6 months</time_frame>
    <description>Ratio of the number of patients who died early</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neoplasm, Plasma Cell</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Geriatric Follow-up (Comprehensive Geriatric Assessment)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A systematic reassessment of geriatric parameters</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Comprehensive Geriatric Assessment</intervention_name>
    <description>A systematic reassessment of geriatric parameters will be performed at 3 and 6 months post-inclusion.</description>
    <arm_group_label>Geriatric Follow-up (Comprehensive Geriatric Assessment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 75 years of age or older,&#xD;
&#xD;
          -  Lymphoid hemopathies (diffuse large cell B-cell lymphoma (DLBCL), follicular lymphoma,&#xD;
             marginal zone lymphoma, Hodgkin's lymphoma and T-cell lymphoma, chronic lymphocytic&#xD;
             leukemia (CLL)) or plasma cell and/or lymphoplasmacytic hemopathies (multiple myeloma&#xD;
             or Waldenström disease).&#xD;
&#xD;
          -  WHO performance index 0-3,&#xD;
&#xD;
          -  Patients requiring first or second line chemotherapy and/or immunotherapy associated&#xD;
             or not to targeted therapy,&#xD;
&#xD;
          -  Patients with a life expectancy of more than 3 months,&#xD;
&#xD;
          -  Persons affiliated or benefiting from a social insurance,&#xD;
&#xD;
          -  Free, informed and written consent signed by the participant and the investigator (at&#xD;
             the latest on the day of inclusion and before any examination required by the&#xD;
             research).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myeloid hemopathies,&#xD;
&#xD;
          -  Patient included in a clinical trial that potentially interferes with the purpose of&#xD;
             the study (geriatric interventional study, early drug study),&#xD;
&#xD;
          -  Patient under court protection, guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent BALARDY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent BALARDY, MD</last_name>
    <phone>05 61 77 64 95</phone>
    <phone_ext>+33</phone_ext>
    <email>balardy.l@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine LE FLOCH</last_name>
    <email>lefloch.s@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent BALARDY</last_name>
      <phone>05 61 77 64 95</phone>
      <phone_ext>+33</phone_ext>
      <email>balardy.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent BALARDY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie LOZANO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loïc YSEBAERT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurore PERROT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>comprehensive geriatric assessment (CGA)</keyword>
  <keyword>quality of life (QoL)</keyword>
  <keyword>autonomy</keyword>
  <keyword>elderly patients</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>immunochemotherapy</keyword>
  <keyword>lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

